Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 36, New York, NY 10065, USA.
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 36, New York, NY 10065, USA.
Clin Lab Med. 2023 Dec;43(4):565-576. doi: 10.1016/j.cll.2023.06.001. Epub 2023 Aug 5.
Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death. Appropriate identification of this entity is critical to mitigate cardiovascular risk factors and ensure appropriate monitoring for the emergence of blood cancer.
癌前克隆性造血是指在其他健康个体的血液中存在体细胞改变。虽然这种情况不被认为是癌症，但它会增加发生血液系统恶性肿瘤的风险，尤其是在那些具有大肿瘤克隆、多种致病性突变和高危突变的患者中。除了增加恶性肿瘤的风险外，克隆性造血还会显著增加心血管事件和死亡的风险。正确识别这种实体对于减轻心血管危险因素和确保对血液癌的出现进行适当监测至关重要。
